Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Chemists at The Scripps Research Institute (TSRI) have devised a new technique for connecting drug molecules to antibodies to make advanced therapies.

8 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

Researchers at The Cancer Institute at NYU Langone Medical Center is leading a $6.25 million, five-year research initiative, funded by the Leukemia & Lymphoma Society, to develop new therapies and advance the cure rate for children and young adults with acute lymphoblastic cancer (ALL), the most common form of childhood cancer.

4 Oct 2013

Research: Children with inherited anti-inflammatory defect may have predisposition to lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, the Journal of the American Society of Hematology (ASH), reveal an important association between the genetic defect, which causes chronic intestinal inflammation and early onset inflammatory bowel disease, and its role in cancer development in infants and children.

3 Oct 2013

Obamacare winners and losers

NPR looks at what the federal government can learn from Massachusetts as health insurance exchanges roll out. Other media outlets check in with insurers, Wall Street traders, health care stakeholders and those who had previously been denied coverage in the individual insurance market.

2 Oct 2013

First Edition: October 1, 2013

Today's headlines detail how the federal government has been shutdown as a result of the ongoing congressional battle over the health law. Still, even as House and Senate lawmakers were unable to overcome this issue to reach a deal to provide funding to continue government operations, Oct. 1 is still the official launch of the overhaul's online insurance marketplaces.

1 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

The prevalence of skin disease exceeds that of obesity, hypertension or cancer. One in three individuals in the United States suffers with a skin disease, with ~2-3% of the American population suffering from psoriasis.

27 Sep 2013

Marriage improves outcomes among patients with cancer, says oncologist

New results from a large retrospective study of the National Cancer Institute's SEER database show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients.

24 Sep 2013

Researchers discover why multiple myeloma recurs after initially effective treatment

Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years.

19 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Inside Jersey magazine names Rutgers Cancer Institute of New Jersey physicians among Top Doctors

Several physicians at Rutgers Cancer Institute of New Jersey have been named as a 'Top Doctor' by Inside Jersey magazine.

17 Sep 2013

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Current criteria for ALK positive lung cancer needs to be redefined

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.

12 Sep 2013

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

The ability to visualize and analyze the spread of viral infections in primary and metastatic tumors is an essential component in characterizing the therapeutic efficacy of oncolytic viruses.

12 Sep 2013

Exposing young girls to ionizing radiation can raise risk of breast cancer later in life

Exposing young women and girls under the age of 20 to ionizing radiation can substantially raise the risk of their developing breast cancer later in life. Scientists may now know why. A collaborative study, in which Berkeley Lab researchers played a pivotal role, points to increased stem cell self-renewal and subsequent mammary stem cell enrichment as the culprits.

12 Sep 2013

Binaytara Foundation, UIC partner to develop Nepal's first blood and marrow transplant unit

The University of Illinois at Chicago and the Binaytara Foundation have partnered to develop Nepal's first blood and marrow transplant unit and to organize the country's first international conference on blood cancers.

12 Sep 2013

Lymphoma News and Research

Further Reading

Phase 3 study of idelalisibin reports positive results in CLL patients

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

Research: Children with inherited anti-inflammatory defect may have predisposition to lymphoma

Obamacare winners and losers

First Edition: October 1, 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Marriage improves outcomes among patients with cancer, says oncologist

Researchers discover why multiple myeloma recurs after initially effective treatment

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Inside Jersey magazine names Rutgers Cancer Institute of New Jersey physicians among Top Doctors

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Current criteria for ALK positive lung cancer needs to be redefined

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

Exposing young girls to ionizing radiation can raise risk of breast cancer later in life

Binaytara Foundation, UIC partner to develop Nepal's first blood and marrow transplant unit

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News